内幕人士在2026年1月22日出售了439K的Apellis股票,收入丰厚,但市场情绪好坏参半。 Insiders sold $439K of Apellis stock on Jan. 22, 2026, amid strong earnings but mixed market sentiment.

2026年1月22日, Apellis制药公司内部人士David Watson、Nur Nicholson和Caroline Baumal集体出售了20 153股股份,平均价格为21.77美元,共计约439 500美元。 On January 22, 2026, Apellis Pharmaceuticals insiders David Watson, Nur Nicholson, and Caroline Baumal collectively sold a combined 20,153 shares at an average price of $21.77, totaling approximately $439,500. 这些交易在证交会档案中披露,其直接所有权分别减少了3%至10%。 The transactions, disclosed in SEC filings, reduced their direct ownership by 3% to 10% each. 库存关闭21.76美元,减少0.25美元,数量低于平均水平。 The stock closed at $21.76, down $0.25, with below-average volume. 该公司在10月30日报告Q3收入丰厚,有167美元EPS和4.5858亿美元收入,比上一年增长133%。 The company reported strong Q3 earnings on October 30, with $1.67 EPS and $458.58 million in revenue, up 133% year-over-year. 分析师维持“机动购买”共识,目标为33.53美元,尽管最近内幕出售可能影响到近期情绪。 Analysts maintain a "Moderate Buy" consensus with a $33.53 target, though recent insider selling may be affecting near-term sentiment.